Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 328 plus Velcade versus Velcade alone in relapsed or refractory multiple myeloma
2006-001904-36Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple myeloma (MM) comparing CNTO 328 + bortezomib with Placebo + bortezomib (2 arms). Primary endpoints: Safety (Part I) and Progression-free survival (Part II). Started Jul 2006; status: completed.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-001904-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001904-36.